Novartis pays $130M for Sironax brain-delivery platform

What's the deal? Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million, taking control of technology designed to move large molecules to targets in the central nervous system.

Why this matters: The blood-brain barrier blocks most drugs from reaching the brain, a longstanding obstacle for treating neurological disease. Sironax's platform is built to shuttle large molecules across that barrier.

What's the endgame? Novartis takes ownership of the technology by exercising an option it held on the platform. The move gives it a route to develop treatments aimed at central nervous system targets.

The signal: Big pharma continues to buy its way into delivery science, betting that solving the brain-access problem unlocks a new class of neurological therapies.

Read more: fiercebiotech.com

Image credit: CodonAUG